{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:39:31Z","timestamp":1792024771315,"version":"4.4.0"},"reference-count":10,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T00:00:00Z","timestamp":1468195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Trichomonas vaginalis is a sexually transmitted protozoan infection resulting in vulvo-vaginitis and altered vaginal discharge in symptomatic women. Trichomoniasis has been implicated in causing adverse pregnancy outcomes such as low birth weight and pre-term labour. Metronidazole is the recommended first-line treatment for trichomonal infection. Other nitroimidazoles, such as tinidazole, are used as alternative regimens with similar activity but at a greater expense. Treatment failure usually represents patient non-compliance or re-infection, although metronidazole resistance has previously been documented. Antimicrobial susceptibility testing for T. vaginalis is currently not available in the UK. Patients with disease unresponsive to first-line treatments pose a major challenge, as therapeutic options are limited. We present the case of a patient with presumed resistant infection during pregnancy, and the additional treatment issues that this presented.<\/jats:p>","DOI":"10.1177\/0956462415601295","type":"journal-article","created":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T23:08:06Z","timestamp":1442617686000},"page":"906-908","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["A case of metronidazole-resistant\n                    <i>Trichomonas vaginalis<\/i>\n                    in pregnancy"],"prefix":"10.1177","volume":"27","author":[{"given":"Georgina L","family":"Forbes","sequence":"first","affiliation":[{"name":"Department of Sexual Health, Cardiff Royal Infirmary, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Drayton","sequence":"additional","affiliation":[{"name":"Department of Sexual Health, Cardiff Royal Infirmary, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin D","family":"Forbes","sequence":"additional","affiliation":[{"name":"Public Health Wales Microbiology Cardiff, University Hospital of Wales, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"key":"bibr1-0956462415601295","doi-asserted-by":"crossref","unstructured":"Sherrard J, Ison C, Moody J, et\u00a0al.\n                      United Kingdom National Guideline on the Management of Trichomonas vaginalis 2014\n                      . London: BASHH.","DOI":"10.1177\/0956462414525947"},{"key":"bibr2-0956462415601295","first-page":"CD000220","volume":"11","author":"G\u00fclmezoglu AM","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr3-0956462415601295","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000157108.32059.8f"},{"key":"bibr4-0956462415601295","first-page":"CD000220","volume":"3","author":"G\u00fclmezoglu AM","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr5-0956462415601295","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2007.02.002"},{"key":"bibr6-0956462415601295","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90567-7"},{"key":"bibr7-0956462415601295","unstructured":"Zentiva. Summary of product characteristics for Flagyl 400\u2009mg tablets, http:\/\/www.medicines.org.uk\/EMC\/medicine\/21216\/SPC\/Flagyl400mgTablets\/ (accessed 30 July 2015)."},{"key":"bibr8-0956462415601295","unstructured":"Pfizer. Summary of product characteristics for Tinidazole 500\u2009mg tablets, http:\/\/www.medicines.org.uk\/emc\/medicine\/1460 (accessed 30 July 2015)."},{"key":"bibr9-0956462415601295","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0b013e31820eb271"},{"key":"bibr10-0956462415601295","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.4.783-793.2004"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462415601295","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462415601295","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462415601295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:35:25Z","timestamp":1777674925000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462415601295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1177\/0956462415601295"],"URL":"https:\/\/doi.org\/10.1177\/0956462415601295","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]}}}